Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

Leukemia

Volumn 16, Issue 9, 2002, Pages 1627-1636

  Larson, R A ^a   Boogaerts, M ^b   Estey, E ^c   Karanes, C ^d   Stadtmauer, E A ^e   Sievers, E L ^f,g   Mineur, P ^h   Bennett, J M ⁱ   Berger, M S ^j   Eten, C B ^j   Munteanu, M ^j   Loken, M R ^k   van Dongen, J J M ^l   Bernstein, I D ^f,g   Appelbaum, F R ^f   Dombret, H ^m   Harousseau, J L ⁿ   Schuster, M ^o   Tallman, M ^p   Theobald, M ^q   Castaigne, S ^r   Ehninger, G ^s   Gramatzki, M ^t   Granena, A ^u   Huijgens, P ^v   Juliusson, G ^w   Lowenberg B ^l   Roy, D C ^x   Spielberger, R ^y   Stenke, L ^z   Voliotis, D ^aa   Aglietta, M ^ab   Burnett, A ^ac   Cambier, N ^ad   Cassileth, P ^ae   Clausen, D D ^af   Coutre, S ^ag   Erba, H ^ah   Esteve, J ^ai   Gobbi, M ^aj   Goldstone, A ^ak   Heil, G ^al   Horst, H A ^am   List, A ^an   Mediavilla, J D ^ao   Minden, M ^ap   Nobile, F ^aq   Parreira, B A B S ^ar   Paul, C ^as   Rai, K ^at   Schenkein, D ^au   Schiller, G ^av   Simonsson, B ^aw   Tarantolo, S ^ax   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h Hopital St Joseph   (Belgium)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j PFIZER INC   (United States)

^k HEMATOLOGICS INC   (United States)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ Centre Hospitaler Regional et Univ   (France)

^o WEILL CORNELL MEDICAL CENTER   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q JOHANNES GUTENBERG UNIVERSITY   (Germany)

^r Hospital A Mignot   (France)

^s UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^t UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^u HOSPITAL DURAN I REYNALS   (Spain)

^v ACADEMIC MEDICAL CENTER   (Netherlands)

^w LINKÖPING UNIVERSITY   (Sweden)

^x MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^y CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^z KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^aa UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^ab MAURIZIANO HOSPITAL   (Italy)

^ac UNIVERSITY OF WALES   (United Kingdom)

^ad UNIV LILLE   (France)

^ae UNIVERSITY OF MIAMI   (United States)

^af STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^ag STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^ah UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^ai HOSPITAL CLÍNIC   (Spain)

^aj UNIVERSITY OF GENOA   (Italy)

^ak UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^al Leibniz Research Laboratory for Biotechnology and Artificial Organs   (Germany)

^am KLINIKUM BRAUNSCHWEIG   (Germany)

^an UNIVERSITY OF ARIZONA   (United States)

^ao HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ap PRINCESS MARGARET HOSPITAL   (Canada)

^aq UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^ar Bone Marrow Transplantation Unit   (Portugal)

^as Huddinge sjh   (Sweden)

^at LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^au TUFTS MEDICAL CENTER   (United States)

^av UNIVERSITY OF CALIFORNIA   (United States)

^aw UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^ax UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Antibody targeted chemotherapy; Calicheamicin; CD33 positive acute myeloid leukemia; Gemtuzumab ozogamicin; Humanized anti CD33 antibody; Therapeutic trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALICHEAMICIN; CD33 ANTIGEN; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; MITOXANTRONE; PARACETAMOL; RECOMBINANT ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ELDERLY CARE; EPISTAXIS; FEMALE; FEVER; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0036733277     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402677     Document Type: Article

References (47)

1. Treatment of acute myelogenous leukemia in older adults
2. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission
3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly
4. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk patients
5. Acute myeloid leukemia
6. Acute myeloid leukemia in the elderly: 'Per spera ad astra'?
7. How I treat older patients with AML
8. Principal results of the Medical Research Council's 8th acute myeloid leukemia trial
9. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
10. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine, arabinoside, and daunorubicin (TAD9) in 150 after standardized first line therapy
11. The management of recurrent acute myelogenous leukemia at a single centre over a fifteen-year period
12. Results of therapy for acute myeloid leukemia in first relapse
13. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence
14. Reinduction chemotherapy for acute nonlymphocytic leukemia
15. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
16. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine
17. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine
18. Management of acute myeloid leukemia in elderly patients
19. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia
20. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
21. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for the treatment of acute myeloid leukemia
22. The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score
23. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
24. Expression of normal myeloid-associated antigens by acute leukemia cells
25. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
26. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia
27. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
28. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
29. An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse
30. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
31. Biologic and genetic features of acute myelogenous leukemia: New insights for therapy
32. A cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
33. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly
34. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia: A Cancer and Leukemia Group B study
35. FLAG is a useful regimen for poor prognosis adult myeloid leukemias and myelodysplastic syndromes
36. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
37. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia
38. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
39. An effective age unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukemia
40. Low-dose ara-C and 1(OH)D3 administration in acute nonlymphoid leukemia: Pilot study
41. Time sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial
42. A randomized phase II study on effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)
43. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid placebo-controlled trial (EMA91 trial)
44. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia
45. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: An active well-tolerated regimen
46. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia
47. Low incidence of hepatic venoocclusive disease after treatment with gemtuzumab ozogamicin (Mylotarg™ CMA-676): Relationship to hematopoietic stem cell transplantation